Intelligence Feed event · Equity · 2026-10-06

    Spyre Therapeutics prices $350 million public offering at $85 per share

    Question

    Spyre Therapeutics prices $350 million public offering at $85 per share

    Direct answer

    Spyre Therapeutics completed the pricing of its $350.0 million common stock offering at $85 per share. The proceeds will be deployed into clinical stage immunology development across multiple indications including rheumatology and dermatology.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-06
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Spyre Therapeutics prices $350 million public offering at $85 per share”, revision 1, evidence through 2026-10-06. https://marketontology.com/market-events/2026-10-06/spyre-therapeutics-prices-350-million-public-offering-at-85-per-share-08560f

    EQUITY
    Spyre Therapeutics prices $350 million public offering at $85 per share
    Spyre Therapeutics completed the pricing of its $350.0 million common stock offering at $85 per share. The proceeds will be deployed into clinical stage immunology development across multiple indications including rheumatology and dermatology.
    SYRE
    Impact
    68
    OCT 6
    SIG
    95%
    SYRE
    Spyre Therapeutics prices $350 million public offering at $85 per share
    Spyre Therapeutics completed the pricing of its $350.0 million common stock offering at $85 per share. The proceeds will be deployed into clinical stage immunology development across multiple indications including rheumatology and dermatology.
    → Issuance of new equity at $85 per share increases outstanding share float while securing $350 million in balance sheet cash for clinical trial advancement.
    Impact
    Spyre Therapeutics completed the pricing of its $350.0 million common stock offering at $85 per share. The proceeds will be deployed into clinical stage immunology development across multiple indications including rheumatology and dermatology.
    Affected
    SYRE
    Transmission
    Issuance of new equity at $85 per share increases outstanding share float while securing $350 million in balance sheet cash for clinical trial advancement.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    SYREequity dilution offset by extended cash runway for Phase 3 trialsMixedintradayPriced public offering of common stock at $85 per share raising $350 million.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month